Trading Signals: ADAP Stock Price Prediction and Forecast (Mon. Oct. 26, 2015 - Fri. May. 28, 2021)(Adaptimmune Therapeutics plc)
| ADAP latest price $5.1600 (-3.73%) ($5.1000 - $5.3800) on Wed. Dec. 19, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.83% (three month average) | RSI | 45 | Latest Price | $5.1600(-3.73%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADAP declines -2% a day on average for past five trading days. | Weekly Trend | ADAP declines -0.2% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADAP advance at 0% a week (0% probability) SMH(19%) GDXJ(13%) UNG(13%) FXI(11%) JETS(11%) | Factors Impacting ADAP price | ADAP will decline at least -2.915% in a week (0% probabilities). XLP(-12%) XLV(-10%) VIXM(-8%) XLB(-7%) SDY(-7%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.915% (StdDev 5.83%) | Hourly BBV | 0 () | Intraday Trend | -2.1% | | | |
|
Resistance Level | $5.6 | 5 Day Moving Average | $5.48(-5.84%) | 10 Day Moving Average | $5.7(-9.47%) | 20 Day Moving Average | $5.6(-7.86%) | To recent high | -63.6% | To recent low | 1% | Market Cap | $N/A | | | | Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom. |